Unknown OBSERVATIONAL NCT04512521

Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma (FUNLUM)

FUNLUM: Functional Lung MRI for Early Treatment Response Assessment and Outcome Prediction for Patients With Severe Eosinophilic Asthma on Anti IL 5 Antibody Therapy

Sponsor: GlaxoSmithKline

Conditions Asthma; Eosinophilic

Interventions Mepolizumab

Updated 9 times since 2020 Last updated: Mar 9, 2023 Started: May 4, 2020 Primary completion: Feb 28, 2025 Completion: Aug 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04512521, this observational or N/A phase trial focuses on Asthma; Eosinophilic and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Oct 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Apr 2023 — Jul 2024 [monthly]

Recruiting
Dec 2021 — Apr 2023 [monthly]

Recruiting

▶ Show 4 earlier versions

Sep 2021 — Dec 2021 [monthly]

Recruiting
Jan 2021 — Sep 2021 [monthly]

Recruiting
Nov 2020 — Jan 2021 [monthly]

Recruiting
Sep 2020 — Nov 2020 [monthly]

Recruiting

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Hannover Medical School

Data source: Hannover Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hanover, Germany